JPWO2019214726A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019214726A5 JPWO2019214726A5 JP2020561817A JP2020561817A JPWO2019214726A5 JP WO2019214726 A5 JPWO2019214726 A5 JP WO2019214726A5 JP 2020561817 A JP2020561817 A JP 2020561817A JP 2020561817 A JP2020561817 A JP 2020561817A JP WO2019214726 A5 JPWO2019214726 A5 JP WO2019214726A5
- Authority
- JP
- Japan
- Prior art keywords
- buprenorphine
- degree
- diffraction pattern
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001736 buprenorphine Drugs 0.000 claims 9
- 239000007971 pharmaceutical suspension Substances 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 7
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- KMHZPJNVPCAUMN-UHFFFAOYSA-N Erbon Chemical compound CC(Cl)(Cl)C(=O)OCCOC1=CC(Cl)=C(Cl)C=C1Cl KMHZPJNVPCAUMN-UHFFFAOYSA-N 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023079918A JP2023106478A (ja) | 2018-05-11 | 2023-05-15 | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 |
| JP2025074417A JP2025121948A (ja) | 2018-05-11 | 2025-04-28 | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670714P | 2018-05-11 | 2018-05-11 | |
| US62/670,714 | 2018-05-11 | ||
| PCT/CN2019/086449 WO2019214726A1 (en) | 2018-05-11 | 2019-05-10 | Long-acting injectable formulations and crystalline forms of buprenorphine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023079918A Division JP2023106478A (ja) | 2018-05-11 | 2023-05-15 | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522306A JP2021522306A (ja) | 2021-08-30 |
| JPWO2019214726A5 true JPWO2019214726A5 (https=) | 2022-05-18 |
| JP2021522306A5 JP2021522306A5 (https=) | 2022-05-18 |
| JP7421804B2 JP7421804B2 (ja) | 2024-01-25 |
Family
ID=68466685
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561817A Active JP7421804B2 (ja) | 2018-05-11 | 2019-05-10 | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 |
| JP2023079918A Pending JP2023106478A (ja) | 2018-05-11 | 2023-05-15 | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 |
| JP2025074417A Pending JP2025121948A (ja) | 2018-05-11 | 2025-04-28 | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023079918A Pending JP2023106478A (ja) | 2018-05-11 | 2023-05-15 | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 |
| JP2025074417A Pending JP2025121948A (ja) | 2018-05-11 | 2025-04-28 | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11524965B2 (https=) |
| EP (1) | EP3790881B1 (https=) |
| JP (3) | JP7421804B2 (https=) |
| KR (2) | KR102839314B1 (https=) |
| CN (1) | CN111954672B (https=) |
| AR (1) | AR117426A1 (https=) |
| AU (1) | AU2019266795B2 (https=) |
| BR (1) | BR112020016576A2 (https=) |
| CA (1) | CA3089256C (https=) |
| MX (1) | MX2020008471A (https=) |
| NZ (1) | NZ766474A (https=) |
| TW (1) | TWI838372B (https=) |
| WO (1) | WO2019214726A1 (https=) |
| ZA (1) | ZA202004582B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020016576A2 (pt) | 2018-05-11 | 2020-12-15 | Alar Pharmaceuticals Inc. | Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina |
| GB202019594D0 (en) * | 2020-12-11 | 2021-01-27 | Univ London Queen Mary | Sustained release formulations of crystalline drugs |
| CN117999079A (zh) * | 2021-08-20 | 2024-05-07 | 苏州恩华生物医药科技有限公司 | 一种包含塞纳布啡的药物组合物 |
| IL317873A (en) * | 2022-06-24 | 2025-02-01 | Alar Pharmaceuticals Inc | Stable pharmaceutical composition of buprenorphine and method of preparation and use thereof |
| CN115317453A (zh) * | 2022-09-01 | 2022-11-11 | 广东嘉博制药有限公司 | 一种缓释微球制剂及其制备方法与用途 |
| EP4719414A2 (en) * | 2023-06-02 | 2026-04-08 | Board of Regents of the University of Nebraska | Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO121631B1 (ro) | 1999-08-27 | 2008-01-30 | Southern Research Institute | Compoziţie cu buprenorfină şi utilizarea acesteia pentru reducerea consumului de heroină şi/sau alcool |
| DE60329515D1 (de) | 2002-10-25 | 2009-11-12 | Euro Celtique Sa | Analoga und prodrugs von buprenorphin |
| CN1263760C (zh) * | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物 |
| DE60224288T2 (de) | 2002-11-25 | 2009-04-16 | Chi Mei Foundation Medical Center | Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel |
| JP2004175706A (ja) * | 2002-11-26 | 2004-06-24 | Chi Mei Foundation Medical Center | 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物 |
| WO2005117830A1 (en) | 2004-06-04 | 2005-12-15 | Camurus Ab | Liquid depot formulations |
| GB0606124D0 (en) | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
| US9272044B2 (en) * | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| GB2481018B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| FR2975912B1 (fr) * | 2011-05-30 | 2013-06-14 | Flamel Tech Sa | Composition a liberation controlee de buprenorphine |
| CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| EP2970188A4 (en) | 2013-03-15 | 2016-10-19 | Vm Therapeutics Llc | NOVEL CRYSTALLINE FORMS |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| GB201404139D0 (en) * | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| CN107660207B (zh) * | 2015-03-10 | 2020-09-29 | 罗德科技公司 | 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法 |
| TWI743193B (zh) * | 2016-09-13 | 2021-10-21 | 昱展新藥生技股份有限公司 | 丁基原啡因緩釋製劑 |
| BR112020016576A2 (pt) | 2018-05-11 | 2020-12-15 | Alar Pharmaceuticals Inc. | Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina |
-
2019
- 2019-05-10 BR BR112020016576-0A patent/BR112020016576A2/pt unknown
- 2019-05-10 AU AU2019266795A patent/AU2019266795B2/en active Active
- 2019-05-10 KR KR1020237020398A patent/KR102839314B1/ko active Active
- 2019-05-10 KR KR1020207035014A patent/KR20210021459A/ko not_active Ceased
- 2019-05-10 NZ NZ766474A patent/NZ766474A/en unknown
- 2019-05-10 US US16/981,745 patent/US11524965B2/en active Active
- 2019-05-10 CA CA3089256A patent/CA3089256C/en active Active
- 2019-05-10 CN CN201980023678.2A patent/CN111954672B/zh active Active
- 2019-05-10 JP JP2020561817A patent/JP7421804B2/ja active Active
- 2019-05-10 EP EP19799555.8A patent/EP3790881B1/en active Active
- 2019-05-10 WO PCT/CN2019/086449 patent/WO2019214726A1/en not_active Ceased
- 2019-05-10 MX MX2020008471A patent/MX2020008471A/es unknown
- 2019-05-10 TW TW108116576A patent/TWI838372B/zh active
- 2019-05-10 AR ARP190101256A patent/AR117426A1/es unknown
-
2020
- 2020-07-23 ZA ZA2020/04582A patent/ZA202004582B/en unknown
-
2022
- 2022-08-26 US US17/896,280 patent/US12522610B2/en active Active
-
2023
- 2023-05-15 JP JP2023079918A patent/JP2023106478A/ja active Pending
-
2025
- 2025-04-28 JP JP2025074417A patent/JP2025121948A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522306A5 (https=) | ||
| AU2020410549B2 (en) | Long-acting injectable formulations of ketamine pamoate salts | |
| KR102839314B1 (ko) | 오래 지속되는 주사용 제제와 부프레노핀 유도체 | |
| JP2013545730A5 (https=) | ||
| KR960004345A (ko) | 2-(2- 아미노-1,6- 디하이드로-6- 옥소-퓨린-9-일)메톡시-1,3- 프로판 디올 유도체 | |
| JP2016510317A5 (https=) | ||
| CA2310141A1 (fr) | Utilisation de derives de benzhydryl sulfinyle pour traiter la somnolence d'origine medicamenteuse | |
| JPH08503203A (ja) | 新規なアリールプロピオン酸誘導体、その製造方法及び鎮痛薬としてのその用途 | |
| RS55812B1 (sr) | Metilfenidatni prolekovi, procesi za njihovo dobijanje i njihova primena | |
| TW201305116A (zh) | 用於治療皮膚疾病及病況之［３－（１－（１ｈ－咪唑－４－基）乙基）－２－甲基苯基］甲醇之酯類前藥 | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2022529720A (ja) | レナリドミドまたは他の免疫調節剤の持続投与 | |
| JPWO2019214726A5 (https=) | ||
| HRP20130092T4 (hr) | Karbamoil-cikloheksani za lijeäśenje akutne manije | |
| JP2016537338A5 (https=) | ||
| RU2017131354A (ru) | Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия | |
| TWI743193B (zh) | 丁基原啡因緩釋製劑 | |
| HRP20140326T1 (hr) | Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat | |
| JP2019529543A5 (https=) | ||
| JP2019531286A5 (https=) | ||
| JP2020533402A5 (https=) | ||
| CA2552855A1 (en) | Azabicyclooctan-3-one derivatives and use thereof | |
| JP2019516722A5 (https=) | ||
| KR890008082A (ko) | 약리학적 활성 카복실산의 에스테르 | |
| JPH05500822A (ja) | 経口的に活性な非中毒性鎮痛薬 |